Новые возможности химиотерапии антрациклин-таксанрезистентного рака молочной железы

1. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2009 г. Вестник Российского онкологического научного центра им. Н.Н.Блохина РАМН. 2011; 22(3) прил. 1: 54–92.
2. American Cancer Society Web site Cancer Facts & Figures 2011 http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pd... 
3. Karamouzis MV, Ioannidis G, Rigatos G. Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. Eur J Cancer Care 2007; 16 (5): 433–8.
4. NCCN Guidelines Version 3.2013, Invasive Breast Cancer BINV-20. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
5. Gennari A, Conte PF, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period. A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104 (8): 1742–50.
6. Dawood SS et al. Is the proportion of patients with synchronous stage IV breast cancer surviving >2 years increasing over time? ASCO 2013, abstr. 524; JCO 2013; V31 (15S): part I, p 12s.
7. Pivot X, Asmar L, Buzdar AU et al. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 2000; 82: 529–34.
8. Jordan MA, Wilson F. Microtubules as a target for a anticancer drugs. Nat Rev Cancer 2004; 4: 253–65.
9. Giaccone G, Pinedo HM. Drug resistance. Oncologist 1996; 1: 82–7.
10. Giai M, Biglia N, Sismondi P. Chemoresistance in breast tumors. Eur J Gynaecol Oncol 1991; 12: 359–73.
11. Sparreboom A, Danesi R, Ando Y et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6: 71–84.
12. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17: 1061–70.
13. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917–31.
14. Mechetner E, Kyshtoobayeva A, Zonis S et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998; 4: 389–98.
15. Valkov NI, Sullivan DM. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma. Semin Hematol 1997; 34: 48–62.
16. Lage H, Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 1999; 125: 
156–65.
17. Fedier A, Schwarz VA, Walt H et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 2001; 93: 571–6.
18. O'Donovan N, Crown J, Stunell H et al. Caspase 3 in breast cancer. Clin Cancer Res 2003; 9: 738–42.
19. Aas T, Børresen AL, Geisler S et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811–4.
20. Paradiso A, Mangia A, Chiriatti A et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005; 16 (Suppl. 4): iv14–9.
21. Martello LA, Verdier-Pinard P, Shen HJ et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an b-tubulin mutation. Cancer Res 2003; 63: 1207–13.
22. Kamath K, Wilson L, Cabral F et al. Beta III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005; 280: 12 902–7.
23. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III b-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999; 80: 1020–5.
24. Fumoleau P, Largillier R, Trillet-Lenoir V et al. Capecitabine (Xeloda) in patients with advanced breast cancer (ABC), previously treated with anthracyclines and taxanes: results of a large phase II study [abstract]. Proc Am Soc Clin Oncol 2002; 21. Abstract 247.
25. Maung K, O'Shaughnessy JA, Sledge GW. Capecitabine/Bevacizumab Compared to Capecitabine Alone in Pretreated Metastatic Breast Cancer: Results of a Phase III Study). Clin Breast Cancer 2003; 3: 375–7.
26. Blum JL, Jones SE, Buzdar AU. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–93.
27. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759–68. 
28. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxanecontaining therapy. Ann Oncol 2003; 14: 1227–33. 
29. Wist EA, Sommer HH, Ostenbad B et al. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004; 43: 186–9.
30. Silvestris N et al. Role of gemcitabine in metastatic breast cancer patients: a short review. Breast 2008; 17 (3): 220–6.
31. Zelek L, Barthier S, Riofrio M et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001; 92 (9): 2267–72.
32. Cardoso F, Bedard PhL, Winer EP et al. International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. J Natl Cancer Inst 2009; 101: 1174–81.
33. Martin M, Ruiz A, Munos M et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8 (3): 187–9.
34. Park IH, Ro J, Lee KS et al. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer et al. Invest New Drugs 2010; 28(5): 659–69.
35. Nelli F, Moscetti L, Natoli G et al. Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. Int J Clin Oncol 2013; 18 (2): 343–9.
36. Kim MK, Kim S-B, Ahn JH et al. Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospective Analysis of 124 Patients. Cencer Res Treat 2008; 40 (2): 81–6.
37. Seidman AD, Brufsky A, Ansari RH et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). J Clin Oncol 2009; 27: 15s (suppl; abstr 1000).
38. Miles D, Vukelja S, Moiseyenko V et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: Analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004; 5 (4): 273–8.
39. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429–37.
40. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004; 22: 2015–25.
41. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32: S3–8.
42. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003; 22: 7280–95.
43. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem 1997; 272: 2534–41.
44. McDaid HM, Mani S, Shen HJ et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002; 8: 2035–43.
45. Lee JJ, Swain SM. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32: S22–6.
46. Roche H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25: 3415–20.
47. Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25: 3421–7.
48. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23: 2726–34.
49. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone b analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25: 3399–406.
50. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25: 3407–14.
51. Puglisi F, Andreetta C, Valent F et al. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 2007; 18: 883–8.
52. Lee FY, Camuso A, Castenada S et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. Proc Am Soc Clin Oncol 2006; 24: Abstr 12 017.
53. Thomas E, Bunnell CA, Vahdat LT et al. A phase I study of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline. Breast Cancer Res Treat Suppl 2003; Abstr. 350.
54. Bunnel C, Vahdat L, Schwatzberg L et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008; 8: 234–41.
55. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210–7.
56. Hortobagyi GN, Perez E, Vdoljak E et al. Analysis of overall survival among patienys with metastatic breast cancer receiving either ixabepilone plus capecitabine or capecitabine alone and review of results from two randomized phase III trials. ASCO Breast 2008; Аbstr. 186.
57. Jassem J, Fein L, Karwal M et al. Ixabepilon plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III stadies. The Breast 2012; 21: 89–94.
58. Lee JJ, Swain SM. The Epothilones: Translating from the Laboratory to the Clinic. Clin Cancer Res 2008; 14 (6): 1618–24.
59. Rivera and Gomez. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Research 2010; 12 (Suppl. 2): 52.

Е.В.Артамонова, Л.В.Манзюк

ФГБУ РОНЦ им. Н.Н.Блохина РАМН, Москва

________________________________________________

E.V.Artamonova, L.V.Manzyuk